Damjanoska K J, Heidenreich B A, Kindel G H, D'Souza D N, Zhang Y, Garcia F, Battaglia G, Wolf W A, Van de Kar L D, Muma N A
Center for Serotonin Disorders Research, Department of Pharmacology, Loyola University Chicago, Stritch School of Medicine, 2160 South First Ave., Maywood, IL 60153, USA.
J Pharmacol Exp Ther. 2004 Jun;309(3):1043-50. doi: 10.1124/jpet.103.062067. Epub 2004 Feb 19.
This study examined the time course and possible mechanisms of agonist-induced desensitization of 5-hydroxytryptamine serotonin 2A receptors in the rat frontal cortex and hypothalamic paraventricular nucleus after 1, 4, and 7 days of treatment with (-)-1-(2,5-dimethoxy-4-iodophenyl)2-aminopropane HCl [(-)-DOI] (1 mg/kg i.p.), a selective 5-HT(2A/2C) receptor agonist. In the frontal cortex, 5-HT-mediated phospholipase C (PLC) enzyme activity decreased by 24 to 30% after 4 to 7 days of (-)-DOI treatment without any significant changes in the guanosine 5'-3-O-(thio)triphosphate-mediated PLC enzyme activity. Additionally, treatment with (-)-DOI did not significantly change the levels of G(alpha11), regulator of G protein signaling (RGS)4, or RGS7 proteins in the frontal cortex, whereas G(alphaq) protein levels in the frontal cortex decreased (47%) only after 7 daily (-)-DOI injections. The functional status of 5-HT(2A) receptors in the hypothalamic paraventricular nucleus was examined using 5-HT(2A) receptor-mediated increases in plasma hormone levels. Plasma adrenocorticotrophic hormone (ACTH) and oxytocin measurements showed that 5-HT(2A) receptor desensitization began after only 1 day of (-)-DOI treatment, and the desensitization continued to increase after 4 and 7 days of treatment (ACTH response decreased 64.2-67.7%; oxytocin response decreased 82.3-90.1%). There were no significant alterations in levels of G(alphaq) or G(alpha11) lamic paraventricular proteins in the hypothanucleus. In conclusion, these results suggest that chronically administered (-)-DOI induces desensitization of 5-HT(2A) receptors in vivo, via a reduction in the ability of 5-HT(2A) receptors to activate G proteins without consistently altering levels of G(alpha) proteins or RGS proteins.
本研究检测了用(-)-1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷盐酸盐[(-)-DOI](1mg/kg腹腔注射)处理1、4和7天后,大鼠额叶皮质和下丘脑室旁核中5-羟色胺(5-羟色胺2A受体)激动剂诱导脱敏的时间进程及可能机制,(-)-DOI是一种选择性5-HT(2A/2C)受体激动剂。在额叶皮质,(-)-DOI处理4至7天后,5-羟色胺介导的磷脂酶C(PLC)酶活性降低了24%至30%,而鸟苷5'-3-O-(硫代)三磷酸介导的PLC酶活性没有任何显著变化。此外,(-)-DOI处理并未显著改变额叶皮质中G(α11)、G蛋白信号调节剂(RGS)4或RGS7蛋白的水平,而仅在每日注射(-)-DOI 7次后,额叶皮质中G(αq)蛋白水平降低(47%)。使用5-HT(2A)受体介导的血浆激素水平升高来检测下丘脑室旁核中5-HT(2A)受体的功能状态。血浆促肾上腺皮质激素(ACTH)和催产素测量结果显示,(-)-DOI处理仅1天后5-HT(2A)受体脱敏就开始了,处理4天和7天后脱敏继续增加(ACTH反应降低64.2%-67.7%;催产素反应降低82.3%-90.1%)。下丘脑室旁核中G(αq)或G(α11)蛋白水平没有显著改变。总之,这些结果表明,长期给予(-)-DOI可在体内诱导5-HT(2A)受体脱敏,其机制是5-HT(2A)受体激活G蛋白的能力降低,而G(α)蛋白或RGS蛋白水平没有持续改变。